Shares of embattled China Evergrande Group rise to 1-1/2-month high

FAN Editor
Evergrande Cultural Tourism City in Suzhou's Taicang
FILE PHOTO: A crane stands at the construction site of Evergrande Cultural Tourism City, a China Evergrande Group project whose construction has halted, in Suzhou’s Taicang, Jiangsu province, China October 22, 2021. REUTERS/Aly Song

November 12, 2021

HONG KONG (Reuters) – Shares of China Evergrande Group extended gains to as much as 16% on Friday afternoon to the highest since Sept. 30, after the cash-strapped developer once again averted a destabilising default with a last minute bond payment this week.

As of 0703 GMT, the Hong Kong-listed company was up 12.25% at HK$2.84, compared with a 0.2% rise in the broader market. The stock has lost 80% so far this year.

Evergrande, the world’s most indebted developer, has been stumbling from deadline to deadline in recent weeks as it grapples with more than $300 billion in liabilities, $19 billion of which are dollar bonds.

The latest payments were made at the end of a 30-day grace period that ended on Wednesday, and were the third time in the past month the company has paid up perilously close to a deadline. The bonds had a total of more than $148 million due.

Evergrande has yet to pay the coupons of offshore bonds issued by unit Scenery Journey due on Nov. 6 worth a combined $82.49 million, which also have a 30-day grace period. It also has coupon payments totalling more than $255 million due on Dec. 28.

Bankers and analysts told Reuters that Beijing would stand firm on policies to curb excess borrowing by property developers even as it makes financing tweaks amid an industry liquidity crunch.

(Reporting by Clare Jim; Editing by Jacqueline Wong)

Free America Network Articles

Leave a Reply

Next Post

AstraZeneca vaccine turns profitable in Q3, drugmaker banking on new orders

FILE PHOTO: A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021. REUTERS/Phil Noble November 12, 2021 (Reuters) -AstraZeneca’s COVID-19 vaccine made a small contribution to earnings in the third quarter and it expects the shot to move to “modest profitability” on new orders after […]

You May Like